Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29262088 | 0.92 | MAPT (0.40) | MAPTKDM4ELCKALDH1A1PKN1 | |
| SCHEMBL31090623 | 0.92 | MAPT (0.40) | MAPTKDM4ELCKALDH1A1PKN1 | |
| SCHEMBL24744939 | 0.86 | SMN1; SMN2 (0.41) | MAPTKDM4ELCKALDH1A1PKN1 | |
| SCHEMBL31090561 | 0.86 | SMN1; SMN2 (0.41) | MAPTKDM4ELCKALDH1A1PKN1 | |
| SCHEMBL31090550 | 0.85 | KDM4E (0.39) | MAPTKDM4ELCKALDH1A1PKN1 | |
| SCHEMBL24744943 | 0.85 | KDM4E (0.39) | MAPTKDM4ELCKALDH1A1PKN1 | |
| SCHEMBL24744938 | 0.84 | TLR8 (0.42) | MAPTKDM4EALDH1A1 | |
| SCHEMBL31090560 | 0.84 | TLR8 (0.42) | MAPTKDM4EALDH1A1 | |
| SCHEMBL24745731 | 0.82 | KDM4E (0.42) | MAPTKDM4ELCKALDH1A1PKN1 | |
| SCHEMBL24744940 | 0.82 | MAPT (0.41) | MAPTKDM4ELCKALDH1A1PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MCL1, MDM2, XIAP | MAPT 1918/4885KDM4E 1943/4885LCK 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.